Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Total Debt: 2011-2023

Historic Total Debt for Capricor Therapeutics (CAPR) over the last 13 years, with Dec 2023 value amounting to $3.4 million.

  • Capricor Therapeutics' Total Debt changed negligibly% to $3.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $3.4 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $3.4 million for FY2023, which is 2.57% down from last year.
  • Per Capricor Therapeutics' latest filing, its Total Debt stood at $3.4 million for FY2023, which was down 2.57% from $3.5 million recorded in FY2022.
  • Capricor Therapeutics' 5-year Total Debt high stood at $4.0 million for FY2021, and its period low was $3.4 million during FY2019.
  • Moreover, its 3-year median value for Total Debt was $3.5 million (2022), whereas its average is $3.6 million.
  • As far as peak fluctuations go, Capricor Therapeutics' Total Debt increased by 17.75% in 2021, and later dropped by 12.83% in 2022.
  • Capricor Therapeutics' Total Debt (Yearly) stood at $3.4 million in 2019, then remained steady at $3.4 million in 2020, then increased by 17.75% to $4.0 million in 2021, then dropped by 12.83% to $3.5 million in 2022, then declined by 2.57% to $3.4 million in 2023.